Compare · ABBV vs GNLX
ABBV vs GNLX
Side-by-side comparison of AbbVie Inc. (ABBV) and Genelux Corporation (GNLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and GNLX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $397.44B, about 3099.1x GNLX ($128.2M).
- Over the past year, ABBV is up 18.1% and GNLX is up 9.2% - ABBV leads by 8.9 points.
- ABBV has been more active in the news (11 items in the past 4 weeks vs 2 for GNLX).
- ABBV has more recent analyst coverage (25 ratings vs 6 for GNLX).
- Company
- AbbVie Inc.
- Genelux Corporation
- Price
- $226.12+0.54%
- $2.85-1.21%
- Market cap
- $397.44B
- $128.2M
- 1M return
- +8.77%
- -3.06%
- 1Y return
- +18.07%
- +9.20%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2023
- News (4w)
- 11
- 2
- Recent ratings
- 25
- 6
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Latest ABBV
- Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aesthetics
- AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
- AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form SD filed by AbbVie Inc.
- AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
- FDA Approval for DECNUPAZ issued to ABBVIE INC
- U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
- SEC Form 144 filed by AbbVie Inc.
- AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
- AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
Latest GNLX
- Head of Regulatory Smalling Ralph sold $563 worth of shares (192 units at $2.93), decreasing direct ownership by 0.28% to 67,611 units (SEC Form 4)
- Director Thomas John sold $29,801 worth of shares (10,000 units at $2.98) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 472,784 units (SEC Form 4)
- Chief Technical Officer Cappello Joseph sold $1,799 worth of shares (605 units at $2.97), decreasing direct ownership by 0.39% to 154,549 units (SEC Form 4)
- Chief Scientific Officer Yu Yong sold $1,798 worth of shares (605 units at $2.97), decreasing direct ownership by 0.40% to 149,706 units (SEC Form 4)
- Head of Regulatory Smalling Ralph sold $804 worth of shares (270 units at $2.98), decreasing direct ownership by 0.40% to 67,803 units (SEC Form 4)
- President and CEO Zindrick Thomas sold $8,226 worth of shares (2,798 units at $2.94), decreasing direct ownership by 0.52% to 532,051 units (SEC Form 4)
- Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
- SEC Form 10-Q filed by Genelux Corporation
- SEC Form DEFA14A filed by Genelux Corporation
- SEC Form DEF 14A filed by Genelux Corporation